Dose Range for Iberdomide Studied in Systemic Lupus Erythematosus

WEDNESDAY, March 16, 2022 -- For patients with systemic lupus erythematosus (SLE), iberdomide at a higher dose is superior to placebo for the rate of response indicating reduction in disease activity, according to a study published in the March 17...

Source: Drugs.com - Pharma News - March 16, 2022 Category: Pharmaceuticals Source Type: news